Neue starke News von Labopharm 901564 - Take it - - 500 Beiträge pro Seite

[Kostolanys Erbe]

Hi Leute,

hier die neuen News von Labopharm:

Labopharm Initiates U.S. Phase III Clinical Trials for Once-Daily Tramadol
1/13/03

Labopharm Inc. (TSX: DDS) today announced the initiation of two Phase III clinical trials in the U.S. for its lead in-house product, a once-daily formulation of Tramadol. Currently available in the U.S. only in immediate-release forms that require dosing four to six times daily, Tramadol generates annual U.S. sales of approximately US$740 million.
Labopharm is conducting two double blind, multi-centre, randomized trials to evaluate the efficacy of once-daily Tramadol in reducing moderate to moderately severe pain in patients suffering from osteoarthritis. The subject population will include men and women aged 40 to 75 and patient dosing will last for 12 weeks. The Company expects to complete the trials by the end of 2003, and the U.S. trial data, in conjunction with the data from ongoing and completed studies, will form the New Drug Application (NDA) filing to the FDA.

`The on schedule initiation of the U.S. studies represents another major step forward in our efforts to bring Tramadol to market globally,`said James R. Howard-Tripp, President and CEO of Labopharm. `Consistent with our plan, we expect to file a drug registration dossier in Europe in the first quarter of 2003 followed by an NDA filing in the U.S. by the end of the year.`

Tramadol is a centrally acting analgesic indicated for moderate to moderately severe pain, which may be associated with such conditions as osteoarthritis, lower back spasm, and other chronic conditions. It reduces pain by binding to u-opioid receptors and by inhibiting the re-uptake of the neurotransmitters norepinephrine and serotonin, offering a unique advantage over other analgesics. Mr. Howard-Tripp noted, `Because Tramadol is well tolerated compared to anti-inflammatory drugs, it can be used by patients who are at risk of developing gastrointestinal bleeding and those with kidney problems. We look forward to bringing the convenience of once-daily dosing of Tramadol`s proven therapeutic benefits to these and other patients.`Current worldwide sales of Tramadol are estimated to be in excess of US$1.3 billion annually.

About Labopharm Inc.

Labopharm Inc. is an international pharmaceutical company specializing in the development of drugs using the Company`s advanced controlled-release technology. Labopharm`s core technology, Contramid(R), can be applied to a wide variety of drugs in solid oral dosage form, in order to improve their oral administration and performance. Labopharm`s proprietary technology is used to develop products that are either bio-equivalent to existing, branded products or are new branded products that improve on existing products by providing the therapeutic benefits of controlled-release drug delivery. Labopharm is a public company whose common shares trade on the Toronto Stock Exchange under the ticker symbol `DDS`.

This press release contains forward-looking statements, which reflect the

Corporation`s current expectations regarding future events. The forward-

looking statements involve risks and uncertainties. Actual events could

differ materially from those projected herein and depend on a number of

factors, including the successful and timely completion of clinical

studies, the uncertainties related to the regulatory process and the

commercialization of the drug thereafter. Investors should consult the

Corporation`s ongoing quarterly filings and annual reports for additional

information on risks and uncertainties relating to these forward-looking

statements. The reader is cautioned not to rely on these forward-looking

statements. The Corporation disclaims any obligation to update these

forward-looking statements.



CONTACT: At Labopharm: James Howard-Tripp, President and CEO, Labopharm, Tel: [phone], jhoward-tripp(at)labopharm.com; At The
Equicom Group: Jason Hogan - Toronto, Investor Relations, Tel: [phone],

jhogan(at)equicomgroup.com; At Feinstein Kean Healthcare: Harriet Ullman -
United States, Media and Investor Relations, Tel: [phone],
hullman(at)fkhealth.com; At National Public Relations: Nathalie Bourque -
Montreal, Investor Relations, Tel: [phone], nbourque(at)national

Kosto

Eure Meinung?

[Speckratte]

..man beachte aber auch die alten schwachen News!

[Kostolanys Erbe]

gegen den Trend + 17 % nach oben...hohe Umsätze:

http://www.stockhouse.ca/comp_info.asp?symbol=DDS&table=list




Eure Meinung? Bin schon lange investiert, habe aber unter 1,80 noch mal aufgestockt, weil ich überzeugt bin von diesem Unternehmen und das Tramadol der Durchbruch sein wird.
Kosto

[Kostolanys Erbe]

Hallo Leute,

Labopharm hält sich bei schwachen Marktumfeld erstaunlich gut. Denke aber, das sie kurzfristig die 4 CAN $ testen werden.

Ist jemand noch in Labopharm investiert?

Kosto

Meinungen sind gefragt!